Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corporation reports news on cell therapy development and commercialization, centered on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson. Company updates commonly cover CARVYKTI sales trends, treatment-site expansion, manufacturing capacity, clinical and real-world data from the CARTITUDE program, and label or evidence developments tied to multiple myeloma care.
Legend Biotech news also follows its broader cell therapy pipeline, including allogeneic and in vivo CAR-T programs such as LUCAR-G39D in B-cell non-Hodgkin lymphoma. Recurring announcements include quarterly financial results, scientific-conference presentations, research and manufacturing priorities, advisory input, and corporate governance updates.
Legend Biotech (NASDAQ: LEGN) reported strong CARVYKTI® growth for Q1 2026, with net trade sales up 62% year-over-year to approximately $597 million and availability in 18 markets and 300+ sites.
Collaboration revenue reached $298.4 million, cash was $834.6 million, and net loss narrowed to $54.3 million, with adjusted net loss at $10.5 million. The company achieved $55 million in Janssen milestones and reports improving margins and manufacturing metrics.
Legend Biotech (NASDAQ: LEGN) announced on May 4, 2026 the engagement of a group of scientific advisors to guide its cell therapy pipeline and research priorities. The advisors bring expertise in oncology, immunology, development, and manufacturing to inform translational research, clinical development, and manufacturing strategy.
The panel aims to support Legend's evolution toward a diversified, next-generation cell therapy pipeline focused on areas of high unmet medical need and expanding patient access.
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, May 12, 2026 to review first quarter 2026 financial results. Senior management will provide an overview of quarterly financial performance via live audio webcast.
A replay and the earnings press release will be available in the Investor Relations section under Events and Presentation approximately two hours after the call concludes.
Legend Biotech (NASDAQ: LEGN) reported Q4 2025 CARVYKTI net trade sales of approximately $555 million and full-year 2025 sales of $1.9 billion, achieved franchise profitability for 2025, and reached >10,000 patients treated. Cash and time deposits were $949 million as of December 31, 2025. The company expanded manufacturing capacity and global commercial footprint, reported improved operating loss versus prior year, and highlighted progress across allogeneic and in vivo pipelines.
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, March 10, 2026 to review fourth-quarter and full-year 2025 results. The call includes a live audio webcast and a replay plus the earnings release available in Investor Relations approximately two hours after the call.
Investors can access the live webcast via the company link; management will provide an overview of quarterly and full-year financial performance.
Legend Biotech (NASDAQ: LEGN) will present six posters on CARVYKTI® (ciltacabtagene autoleucel) at the Tandem Meetings, Feb 4-7, 2026, summarizing clinical and real-world evidence across CARTITUDE trials. Presentations highlight consistent, durable efficacy and safety signals and note clinically meaningful quality-adjusted survival gains, especially when CARVYKTI is used earlier in the multiple myeloma treatment continuum. CARVYKTI is the first and only BCMA-targeted CAR-T approved for patients with at least one prior therapy and is commercially available in 14 countries. The release also details important safety information, including CRS, neurologic toxicities, and warnings from CARTITUDE-1 and -4.
Legend Biotech (NASDAQ: LEGN) provided commercial and clinical updates and outlined 2026 priorities ahead of its Jan 14, 2026 J.P. Morgan presentation. Key highlights: CARVYKTI has treated >10,000 patients to date; global availability expanded to >279 sites across 14 markets; Raritan manufacturing expansion adds installed capacity to support treatment of up to 10,000 patients annually. Regulatory labels in the U.S. and EU now include an overall survival benefit from CARTITUDE-4. Median PFS of 50.4 months reported for certain patients. Company expects CARVYKTI franchise profitability in FY2025 and company-wide operating profit in 2026. Cash and time deposits were approximately $1.0 billion as of Sept 30, 2025. First-in-human in vivo dosing completed; in vivo readouts expected 2H 2026.
Legend Biotech (NASDAQ: LEGN) announced that CEO Ying Huang, Ph.D. will present company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT.
The presentation will be available via a live webcast on Legend Biotech's Investor Relations website, and a replay will be posted approximately 48 hours after the live event.
Legend Biotech (NASDAQ: LEGN) reported long-term and first-in-human CAR-T data at ASH 2025 for CARVYKTI® (ciltacabtagene autoleucel) and allogeneic candidate LUCAR-G39D.
Key clinical highlights: median PFS of 50.4 months in triple-class-exposed patients after one CARVYKTI® infusion; CARTITUDE-4 standard-risk 30-month PFS 71.0% (CARVYKTI®) vs 43.2% (SOC); as-treated 30-month PFS 80.5%. All 26 patients with 12-month MRD-negative CR remained progression-free at 30 months. LUCAR-G39D (N=16) showed ORR 75% and CR 37.5% with manageable safety at median follow-up 6.1 months.
Safety: CARVYKTI® trials (N=285) reported CRS in 84% (Grade ≥3, 4%), ICANS in 13%, and parkinsonism in 3%. LUCAR-G39D reported CRS in 56.3% and serious AEs in 25% of patients. The company noted >9,000 patients treated globally.
Legend Biotech (NASDAQ: LEGN) announced the official opening of a 31,000-square-foot state-of-the-art R&D facility at 2300 Market Street, Philadelphia on November 13, 2025. The site is fully operational and will support CAR-T research and development across potential oncology and immunology indications.
The Philadelphia center expands Legend’s U.S. footprint (company employs over 1,400 U.S. staff), will hire approximately 55 full-time team members, and complements existing R&D in Piscataway plus manufacturing sites in Raritan and Morris Plains, New Jersey.